1 January 2015 in World Journal of Hepatology
JTJavier Tejeda-Maldonado
JAJonathan Aguirre-Valadez
+4
Hepatocellular carcinoma (HCC) is one of the most common malignancies leading to high mortality rates in the general population; in cirrhotic patients, it is the primary cause of death. The diagnosis is usually delayed in spite of at-risk population screening recommendations, i.e., patients infected with hepatitis B or C virus. Hepatocarcinogenesis hinges on a great number of genetic and molecular abnormalities that lead to tumor angiogenesis and foster their dissemination potential. The diagnosis is mainly based on imaging studies such as computed tomography and magnetic resonance, in which lesions present a characteristic classical pattern of early arterial enhancement followed by contrast medium "washout" in late venous phase. On occasion, when imaging studies are not conclusive, biopsy of the lesion must be performed to establish the diagnosis. The Barcelona Clinic Liver Cancer staging method is the most frequently used worldwide and recommended by the international guidelines of HCC management. Currently available treatments include tumor resection, liver transplant, sorafenib and loco-regional therapies (alcoholization, radiofrequency ablation, chemoembolization). The prognosis of hepatocarcinoma is determined according to the lesion's stage and in cirrhotic patients, on residual liver function. Curative treatments, such as liver transplant, are sought in patients diagnosed in early stages; patients in more advanced stages, were not greatly benefitted by chemotherapy in terms of survival until the advent of target molecules such as sorafenib.
22 February 2022 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Background: The early clinical predictors of respiratory failure in Latin Americans with Guillain–Barré syndrome (GBS) have scarcely been studied. This is of particular importance since Latin America has a high frequency of axonal GBS variants that may imply a worse prognosis.Methods: We studied 86 Mexican patients with GBS admitted to theInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, a referral center of Mexico City, to describe predictors of invasive mechanical ventilation (IMV).Results: The median age was 40 years (interquartile range: 26–53.5), with 60.5% men (male-to-female ratio: 1.53). Most patients (65%) had an infectious antecedent (40.6% gastrointestinal). At admission, 38% of patients had a Medical Research Council (MRC) sum score <30. Axonal subtypes predominated (60.5%), with acute motor axonal neuropathy being the most prevalent (34.9%), followed by acute inflammatory demyelinating polyneuropathy (32.6%), acute motor sensory axonal neuropathy (AMSAN) (25.6%), and Fisher syndrome (7%). Notably, 15.1% had onset in upper limbs, 75.6% dysautonomia, and 73.3% pain. In all, 86% received either IVIg (9.3%) or plasma exchange (74.4%). IMV was required in 39.5% patients (72.7% in AMSAN). A multivariate model without including published prognostic scores yielded the time since onset to admission <15 days, axonal variants, MRC sum score 4, and dysautonomia as predictors.Conclusion: These results suggest that EGRIS is a good prognosticator of IMV in GBS patients with a predominance of axonal electrophysiological subtypes, but other early clinical data should also be considered.
26 April 2016 in BMJ Case Reports
APAdriana Guadalupe Peña-Romero
Adriana Guadalupe Peña-Romero
JDJosé Manuel Díaz-González
José Manuel Díaz-González
JDJudith Domínguez-Cherit
19 June 2018 in Postgraduate Medical Journal
JNJorge Adrián Nuñez-Zuno
IJIván Josué Jiménez-González
Iván Josué Jiménez-González
A 34-year-old woman with a history of anorexia nervosa and severe malnutrition (body mass index of 6, weight of 31.7 lbs) was hospitalised for multidisciplinary management. Three weeks after progressive enteral nutrition via nasogastric tube, the patient developed acute intense abdominal pain. CT angiography revealed gastric pneumatosis with submucosal thickening associated with significant intrahepatic portal venous gas, and no evidence of mesenteric ischaemia (figure 1). Endoscopic evaluation showed areas of patchy mucosal …
4 April 2017 in Journal of Stroke and Cerebrovascular Diseases
ECEduardo Carrillo-Maravilla
Eduardo Carrillo-Maravilla
20 March 2026 in Revista de Investigación Clínica
JAJuan José Aguilar-Lugo-Gerez
Juan José Aguilar-Lugo-Gerez
Autosomal dominant polycystic kidney disease (ADPKD) is the leading monogenic cause of end-stage kidney disease (ESKD). Because disease-modifying therapy is costly and can cause adverse effects, identifying patients most likely to benefit is essential. We developed and internally validated a model to predict ESKD by age 80 in class 1 ADPKD, hypothesizing that combining baseline eGFR with an exponential estimate of kidney growth would improve forecasting. We retrospectively analyzed 142 adults with class 1 ADPKD followed at a tertiary center in Mexico City (2012-2023). Total kidney volume (TKV) was measured by the ellipsoid method and eGFR by CKD-EPI 2021. Data were split 50/50 into derivation and validation sets. Future eGFR was modeled using baseline eGFR plus an exponential TKV growth surrogate; ESKD risk (eGFR <15ml/min/1.73m2) was derived from the standard normal cumulative distribution. Performance was compared with the Mayo Clinic Predictive Model (MCPM) and a Cox model. In validation, the model achieved adjusted R2=0.858 (vs. 0.830 for MCPM). ESKD prediction showed excellent discrimination (C-index=0.94) and calibration, comparable to Cox (C-index=0.95). This approach supports individualized lifetime ESKD risk prediction in class 1 ADPKD to guide targeted therapy and resource allocation.